Overview

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

Status:
Terminated
Trial end date:
2018-04-06
Target enrollment:
Participant gender:
Summary
The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.
Phase:
Phase 1
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.